AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin treatments, has granted 102,880 restricted stock units (RSUs) to newly hired non-executive employees. The RSUs were approved under the AEON 2025 Inducement Incentive Plan, with a grant and vesting commencement date of May 21, 2025. The RSUs will vest over a four-year period, with 25% vesting annually. These awards serve as employment inducements and comply with Section 711 of NYSE American LLC Company Guide.
AEON Biopharma (NYSE: AEON), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di trattamenti a base di tossina botulinica, ha assegnato 102.880 unità azionarie vincolate (RSU) ai nuovi dipendenti non dirigenziali. Le RSU sono state approvate nell'ambito del Piano Incentivi di Induzione AEON 2025, con data di concessione e inizio maturazione il 21 maggio 2025. Le RSU matureranno in un periodo di quattro anni, con il 25% che matura ogni anno. Questi premi fungono da incentivi all'assunzione e sono conformi alla Sezione 711 della Guida alle Società NYSE American LLC.
AEON Biopharma (NYSE: AEON), una compañía biofarmacéutica en etapa clínica que desarrolla tratamientos con toxina botulínica, ha otorgado 102,880 unidades restringidas de acciones (RSU) a empleados no ejecutivos recién contratados. Las RSU fueron aprobadas bajo el Plan de Incentivos de Inducción AEON 2025, con fecha de concesión y inicio de adquisición el 21 de mayo de 2025. Las RSU se consolidarán durante un periodo de cuatro años, con un 25% consolidándose anualmente. Estos premios sirven como incentivos de empleo y cumplen con la Sección 711 de la Guía para Empresas de NYSE American LLC.
AEON Biopharma (NYSE: AEON)는 보툴리눔 독소 치료제를 개발하는 임상 단계의 생명공학 회사로, 새로 채용된 비임원 직원들에게 102,880개의 제한 주식 단위(RSU)를 부여했습니다. 이 RSU는 AEON 2025 유인 인센티브 플랜에 따라 승인되었으며, 부여 및 권리 취득 시작일은 2025년 5월 21일입니다. RSU는 4년 기간에 걸쳐 매년 25%씩 권리가 취득됩니다. 이 상여는 고용 유인책으로서 NYSE American LLC 회사 가이드의 섹션 711을 준수합니다.
AEON Biopharma (NYSE : AEON), une société biopharmaceutique en phase clinique développant des traitements à base de toxine botulique, a accordé 102 880 unités d'actions restreintes (RSU) à des employés non cadres nouvellement embauchés. Les RSU ont été approuvées dans le cadre du Plan d'Incitation AEON 2025, avec une date d'attribution et de début d'acquisition fixée au 21 mai 2025. Les RSU seront acquises sur une période de quatre ans, avec 25 % acquises chaque année. Ces récompenses servent d'incitations à l'emploi et sont conformes à la Section 711 du Guide des Sociétés NYSE American LLC.
AEON Biopharma (NYSE: AEON), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das Botulinumtoxin-Behandlungen entwickelt, hat 102.880 Restricted Stock Units (RSUs) an neu eingestellte nicht-exekutive Mitarbeiter vergeben. Die RSUs wurden im Rahmen des AEON 2025 Inducement Incentive Plans genehmigt, mit einem Gewährungs- und Beginn-Datum der Vesting-Periode am 21. Mai 2025. Die RSUs werden über einen Zeitraum von vier Jahren mit einer jährlichen Vesting-Rate von 25 % freigegeben. Diese Auszeichnungen dienen als Anreiz für die Beschäftigung und entsprechen Abschnitt 711 des NYSE American LLC Company Guide.
- None.
- None.
IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today reported the grant in May of 102,880 restricted stock units (RSUs) of the Company’s common stock to newly hired non-executive employees of the company. The awards were approved by the Company’s Board of Directors under the AEON 2025 Inducement Incentive Plan, which a grant date and vesting commencement date of May 21, 2025.
The RSUs vest over four years,
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Source: AEON Biopharma
FAQ
What type of stock compensation did AEON Biopharma (AEON) grant to new employees in May 2025?
What is the vesting schedule for AEON Biopharma's May 2025 RSU grants?
Why did AEON Biopharma issue these RSUs in May 2025?
What is AEON Biopharma's main business focus?
